Repligen (NASDAQ:RGEN) Upgraded to Hold at StockNews.com

StockNews.com upgraded shares of Repligen (NASDAQ:RGEN) from a sell rating to a hold rating in a research note published on Friday morning.

A number of other research analysts have also recently issued reports on RGEN. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $205.00 price target on shares of Repligen in a report on Thursday, September 26th. Wolfe Research assumed coverage on Repligen in a report on Thursday, November 14th. They issued a “peer perform” rating for the company. Canaccord Genuity Group assumed coverage on Repligen in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target for the company. Finally, Canaccord Genuity Group began coverage on Repligen in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target for the company. Six research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, Repligen has an average rating of “Moderate Buy” and a consensus price target of $185.20.

Repligen Stock Up 4.8 %

Shares of NASDAQ RGEN opened at $149.90 on Friday. The stock has a market cap of $8.40 billion, a PE ratio of -405.12, a PEG ratio of 4.64 and a beta of 0.97. The business has a fifty day moving average of $144.96 and a two-hundred day moving average of $142.34. Repligen has a 52-week low of $113.50 and a 52-week high of $211.13. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The company had revenue of $154.87 million during the quarter, compared to analysts’ expectations of $153.34 million. During the same period last year, the business earned $0.23 earnings per share. The business’s revenue was up 9.7% on a year-over-year basis. As a group, equities research analysts expect that Repligen will post 1.54 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Repligen

Several institutional investors have recently modified their holdings of RGEN. International Assets Investment Management LLC acquired a new position in shares of Repligen during the 2nd quarter worth about $33,000. TD Asset Management Inc lifted its stake in Repligen by 2.1% in the 2nd quarter. TD Asset Management Inc now owns 58,965 shares of the biotechnology company’s stock valued at $7,433,000 after acquiring an additional 1,233 shares in the last quarter. North Star Asset Management Inc. lifted its stake in Repligen by 1.6% in the 2nd quarter. North Star Asset Management Inc. now owns 93,724 shares of the biotechnology company’s stock valued at $11,815,000 after acquiring an additional 1,518 shares in the last quarter. Norden Group LLC lifted its stake in Repligen by 32.2% in the 2nd quarter. Norden Group LLC now owns 3,930 shares of the biotechnology company’s stock valued at $495,000 after acquiring an additional 958 shares in the last quarter. Finally, Acadian Asset Management LLC bought a new stake in Repligen in the 2nd quarter valued at approximately $157,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.